@article{df451d73aafa4072b520df303bdeab4a,
title = "Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy",
abstract = "The tumor microenvironment contributes to disease progression through multiple mechanisms, including immune suppression mediated in part by fibroblast activation protein (FAP)-expressing cells. Herein, a review of FAP biology is presented, supplemented with primary data. This includes FAP expression in prostate cancer and activation of latent reservoirs of TGF-β and VEGF to produce a positive feedback loop. This collectively suggests a normal wound repair process subverted during cancer pathophysiology. There has been immense interest in targeting FAP for diagnostic, monitoring and therapeutic purposes. Until recently, this development has outpaced an understanding of the biology; impeding optimal translation into the clinic. A summary of these applications is provided with an emphasis on eliminating tumor-infiltrating FAP-positive cells to overcome stromal barriers to immuno-oncological responses.",
keywords = "FAP, TGF-β, fibroblast activation protein, immunotherapy, prostate cancer, stroma, wound healing",
author = "Brennen, {W. Nathaniel} and {J Thorek}, {Daniel L.} and Wen Jiang and Krueger, {Timothy E.} and Lizamma Antony and Denmeade, {Samuel R.} and Isaacs, {John T.}",
note = "Funding Information: The authors would like to acknowledge the SKCCC Flow Cytometry and Tissue Services Cores supported by the SKCCC Cancer Center Support Grant [CCSG, (P30 CA006973)]. Funding Information: The work was supported by Abbvie (C109738FE, [WN Brennen]), Allegheny Health Network-Johns Hopkins University Cancer Research Fund (WN Brennen, DLJ Thorek), Emerson Collective Cancer Research Fund (643396, [WN Brennen, DLJ Thorek]), the Department of Defense (W81XWH-17-1-0528, [WN Brennen]), W81XWH-16-1-0410 (JT Isaacs, SR Denmeade), and the NIH-Prostate SPORE Grant (P50 CA058236, [SR Denmeade, JT Isaacs]). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2021 Future Medicine Ltd.",
year = "2021",
month = feb,
doi = "10.2217/imt-2020-0066",
language = "English",
volume = "13",
pages = "155--175",
journal = "Immunotherapy",
issn = "1750-743X",
number = "2",
}